Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 322

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 322
---
     |           |   98.4 |     |                |   4,072.8 |     |                |   3,949.0 |

Notes:

| (1) | Values in millions of US Dollars. |

| (2) | Corresponding data and multiples continued in table below. |

| (3) | Source: S&P Capital IQ. |

182

Comparable Company Analysis (Continued)

| Company Name                                       |     | Sales          
 (TTM)($)(1)(2) |           |     | EBITDA         
 (TTM)($)(1)(2) |          |   |     | EBIT           
 (TTM)($)(1)(2) |          |   |     | EV /  
 Sales |       |     | EV /   
 EBITDA |       |     | EV / 
 EBIT |       |
| Amgen Inc. (NasdaqGS:AMGN)                         |     |                |  30,934.0 |     |                | 11,533.0 |   |     |                |  6,459.0 |   |     |       | 7.3x  |     |        | 19.7x |     |      | 35.2x |
| Pacira BioSciences, Inc. (NasdaqGS:PCRX)           |     |                |     690.3 |     |                |    175.3 |   |     |                |    101.1 |   |     |       | 1.2x  |     |        | 4.7x  |     |      | 8.1x  |
| CVS Health Corporation (NYSE:CVS)                  |     |                | 361,855.0 |     |                | 16,136.0 |   |     |                | 11,586.0 |   |     |       | 0.4x  |     |        | 8.5x  |     |      | 11.9x |
| Pfizer Inc. (NYSE:PFE)                             |     |                |  55,165.0 |     |                |  9,950.0 |   |     |                |  3,270.0 |   |     |       | 4.1x  |     |        | 22.8x |     |      | 69